Indian researchers identified non-tuberculous mycobacteria from bovine clinical samples, finding Mycobacterium vaccae to ...

Proposed dates for the arrival of the first humans in the Americas span more than 100,000 years. At one end sits Cerutti, a site in California that Holen and colleagues dated to about 130,000 years ...

Cellectis (NASDAQ:CLLS) outlined plans to advance two preclinical in vivo gene-editing candidates for severe forms of dyslipidemia, targeting hypertriglyceridemia and hypercholesterolemia through ...

Ovarian cancer remains the deadliest of the gynecologic malignancies, a distinction earned not because it is the most common ...

Patent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall ...

Foghorn Therapeutics said on Thursday it has discontinued development of an experimental cancer drug partnered with Eli Lilly ​after it failed to show enough ‌benefit in an early-stage trial. The ...

Ernexa Therapeutics announced highly encouraging results from three core Investigational New Drug (IND)-enabling safety studies of ERNA-101, its lead synthetic, allogeneic induced mesenchymal stromal ...

Part A of LIGHTHOUSE Trial reinforce ATSN-201’s favorable safety profile and durable structural and functional benefits in ...

Across repeat-dose GLP toxicology, tumorigenicity and biodistribution studies, ERNA-101 demonstrated a favorable nonclinical ...

Proviruses are widespread components of prokaryotic genomes, yet their characterization is impeded by border identification ...

Tuesday, Ernexa Therapeutics ( ERNA) said it has been selected for the Emerging Track at the 2026 Cell & Gene Meeting on the Mesa, where CEO Sanjeev Luther will present the company's oncology strategy ...

Ernexa selected for the Emerging Track, recognizing the Company among emerging innovators in the cell and gene therapy sector ...